Evidenced-Based Approach to Oropharynx Cancer, 2023 (2023 AMW) Session
2023 AAO-HNSF Annual Meeting & OTO Experience
PROGRAM DESCRIPTION: HPV-associated oropharynx squamous cell carcinoma (OPSCC) is now one of the most common cancers faced by the Otolaryngology community. Treatment strategies for these patients can be controversial and continue to evolve rapidly because of new technologies including proton therapy, novel systemic therapies including immunotherapy and transoral robotic surgery (TORS). Current treatment approaches vary widely among institutions and national consensus guidelines remain vague. This expert panel presentation will review cutting-edge research and the current best evidence to guide management decisions relevant to general otolaryngologists and head and neck specialists alike with a focus on the role of TORS in a multidisciplinary setting.OUTCOME OBJECTIVE 1: To understand recent advances in the treatment of oropharynx squamous cell carcinoma (OPSCC).OUTCOME OBJECTIVE 2: To describe the current evidence supporting treatment strategies for OPSCC.OUTCOME OBJECTIVE 3: To understand the rational application of transoral robotic surgery (TORS) to OPSCC.BACKGROUND STATEMENT: Management of oropharynx squamous cell carcinoma (OPSCC) continues to evolve, and otolaryngologists can be challenged to stay current. This expert panel presentation will review cutting-edge research and current best evidence to support the contemporary treatment of OPSCC.